Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study

References

• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 May;5(5):333–340.
   PubMed Web of Science ®Google Scholar
• Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015 Oct 7;36(38):2576–2584.
   PubMed Web of Science ®Google Scholar
• Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC-Heart Fail. 2018 Jun;6(6):489–498.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 Oct;383(15):1436–1446.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020 Oct 8;383(15):1413–1424.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 Nov 21;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Ameri P, Bertero E, Maack C, et al. Medical treatment of heart failure with reduced ejection fraction: the Dawn of a new era of personalized treatment? Eur Heart J Cardiovasc Pharmacother. 2021 May 26;7:539–546.
   PubMed Web of Science ®Google Scholar
• Mullens W, Damman K, Harjola V-P, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 Feb;21(2):137–155.
   PubMed Web of Science ®Google Scholar
• Maddox TM, Januzzi JL, Allen LA, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2021 Feb 16;77(6):772–810.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599–3726.
   PubMed Web of Science ®Google Scholar
• Almufleh A, Mielniczuk LM, Zinoviev R, et al. Profound vasoplegia during Sacubitril/valsartan treatment after heart transplantation. Can J Cardiol. 2018 Mar;34(3):343.e5–343.e7.
   PubMed Web of Science ®Google Scholar
• Jefferis JM, McGowan TE, John G. Acute kidney injury related to sacubitril/valsartan injury. Intern Med J. 2020 May;50(5):640–641.
   PubMed Web of Science ®Google Scholar
• Tan NY, Deng Y, Yao X, et al. Renal outcomes in patients with systolic heart failure treated with Sacubitril-valsartan or angiotensin converting enzyme inhibitor/angiotensin receptor blocker. Mayo Clin Proc Innovations Qual Outcomes. 2021 Apr;5(2):286–297.
   PubMedGoogle Scholar
• Nadkarni GN, Ferrandino R, Chang A, et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care. 2017 Nov;40(11):1479–1485.
   PubMed Web of Science ®Google Scholar
• Hahn K, Ejaz AA, Kanbay M, et al. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016 Nov 16;12(12):711–712.
   PubMed Web of Science ®Google Scholar
• Szalat A, Perlman A, Muszkat M, et al. Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf. 2018 Mar;41(3):239–252.
   PubMed Web of Science ®Google Scholar
• Spannella F, Marini M, Giulietti F, et al. Renal effects of Sacubitril/valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study. Intern Emerg Med. 2019 Nov;14(8):1287–1297.
   PubMed Web of Science ®Google Scholar
• Kuster GM, Pfister O. Chronic heart failure: advances in pharmacological treatment and future perspectives. Swiss Med Wkly. 2019 Mar 11; 149. DOI:10.4414/smw.2019.20036.
   Web of Science ®Google Scholar
• Butler J, Januzzi JL, Rosenstock J. Management of heart failure and type 2 diabetes mellitus: maximizing complementary drug therapy. Diabetes Obesity Metab. 2020 Aug;22(8):1243–1262.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014 Jul;16(7):817–825.
   PubMed Web of Science ®Google Scholar
• Feng Y, Yin Y, Deng R, et al. Renal safety and efficacy of angiotensin receptor-neprilysin inhibitor: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2020 Dec;45(6):1235–1243.
   PubMed Web of Science ®Google Scholar
• Brignone J, Assersen KB, Jensen M, et al. Protection of kidney function and tissue integrity by pharmacologic use of natriuretic peptides and neprilysin inhibitors [Review]. Pflugers Arch. 2021 Apr;473(4):595–610.
   PubMed Web of Science ®Google Scholar
• Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010 Apr;50(4):401–414.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012 Oct 20;380(9851):1387–1395.
   PubMed Web of Science ®Google Scholar
• Kim YS, Brar S, D’Albo N, et al. Five years of sacubitril/valsartan-a safety analysis of randomized clinical trials and real-world pharmacovigilance. Cardiovasc Drugs Ther. 2021. DOI:10.1007/s10557-021-07210-1.
   Web of Science ®Google Scholar
• O’Neill J, Fasching A, Pihl L, et al. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol. 2015 Aug 1;309(3):F227–34.
   PubMed Web of Science ®Google Scholar
• Iskander C, Cherney DZ, Clemens KK, et al. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. Cmaj. 2020 Apr 6;192(14):E351–e60.
   PubMed Web of Science ®Google Scholar
• Rampersad C, Kraut E, Whitlock RH, et al. Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study. Am J Kidney Dis. 2020 Oct;76(4):471–9.e1.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Fioretto P, Johnsson K, et al. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016 Jun;29(3):391–400.
   PubMed Web of Science ®Google Scholar
• Donnan JR, Grandy CA, Chibrikov E, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019 Feb 1;9(1):e022577.
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Thorpe KE. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab. 2019 Aug;21(8):1996–2000.
   PubMed Web of Science ®Google Scholar
• Menne J, Dumann E, Haller H, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. PLoS Med. 2019 Dec;16(12):e1002983.
   PubMed Web of Science ®Google Scholar
• Cahn A, Melzer-Cohen C, Pollack R, et al. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis. Diabetes Obes Metab. 2019 Feb;21(2):340–348.
   PubMed Web of Science ®Google Scholar
• Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clin Sci (Lond). 2018 Jun 29;132(12):1329–1339.
   PubMed Web of Science ®Google Scholar
• Chen C, Wu B, Zhang CY, et al. Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol. 2021 Jun;95:107498.
   PubMed Web of Science ®Google Scholar